Comparing the Standard and Electronic Versions of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale: A Validation Study

Solomon, Todd M.; Barbone, Jordan M.; Feaster, H. Todd; Miller, David S.; DeBros, Guy; Murphy, Cynthia A.; Michalczuk, Diana

doi:10.14283/jpad.2019.27

Cited by 3 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 In addition, the different findings between the primary and the secondary outcomes also support the notion that the ADAS-cog is the gold standard for the AD clinical trials. 30 In terms of the safety domain, the current study found that all three doses (500, 750, and 1000 mg/day) of benzoate and placebo had similar performance (Table S2). In accordance, the previous studies using flexible-dose sodium benzoate also showed a similar safety profile with that of placebo in early-phase AD (250-750 mg/day), 17 late-life depression (250-1500 mg/day), 20 MCI (250-1500 mg/day), 21 and BPSD (250-1500 mg/day).…”

Section: Discussionmentioning

confidence: 65%

“…It has been well known that early detection and treatment is essential for the outcome of Alzheimer's disease 45 . In addition, the different findings between the primary and the secondary outcomes also support the notion that the ADAS‐cog is the gold standard for the AD clinical trials 30 …”

Section: Discussionmentioning

confidence: 76%

“… 45 In addition, the different findings between the primary and the secondary outcomes also support the notion that the ADAS‐cog is the gold standard for the AD clinical trials. 30 …”

Section: Discussionmentioning

confidence: 99%

“…The primary outcome measure was the Alzheimer's Disease Assessment Scale‐cognitive subscale (ADAS‐cog) 29 measured at weeks 0, 8, 16, and 24. The ADAS‐cog is the most popular and gold standard cognitive assessment instrument used in AD clinical trials 30 . It consists of 11 tasks, including word recall, naming, commands, constructional praxis, ideational praxis, orientation, word recognition, instructions remembering, spoken language ability, word‐finding difficulty, and comprehension.…”

Section: Methodsmentioning

confidence: 99%

“…The ADAS‐cog is the most popular and gold standard cognitive assessment instrument used in AD clinical trials. 30 It consists of 11 tasks, including word recall, naming, commands, constructional praxis, ideational praxis, orientation, word recognition, instructions remembering, spoken language ability, word‐finding difficulty, and comprehension. Its scores range from 0 (best) to 70 (worst).…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

Lane

Wang

Lin

2022

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim Previous pilot studies suggest that sodium benzoate may be a potential cognitive enhancer for patients with Alzheimer's disease (AD), schizophrenia, or late‐life depression. Especially for AD treatment, a confirmatory trial with predictive biomarkers is urgently needed. This study aimed to confirm benzoate as a novel treatment for AD and to discover its optimal dose and biomarkers. Methods A 24‐week, dose‐finding, randomized, double‐blind, placebo‐controlled trial, with clinical measurements at weeks 0, 8, 16, and 24, was conducted in three major medical centers in Taiwan. Among 154 patients screened for AD, 149 were eligible and randomized to one of the four treatments: (i) benzoate 500 group (fixed 500 mg/day); (ii) benzoate 750 (500 mg/day for the first 4 weeks, 750 mg/day from the 5th week); (iii) benzoate 1000 (500 mg/day for the first 4 weeks, 1000 mg/day from the 5th week); and (iv) placebo. The primary outcome measure was AD assessment scale‐cognitive subscale (ADAS‐cog). Results The benzoate 1000 group performed best in improving ADAS‐cog (P = 0.026 at week 24), with female advantage. Higher plasma catalase at baseline predicted better outcome. Benzoate receivers tended to have higher catalase and glutathione than placebo recipients after treatment. The four intervention groups showed similar safety profiles. Conclusions By enhancing two vital endogenous antioxidants, catalase and glutathione, sodium benzoate therapy improved cognition of patients with AD, with higher baseline catalase predicting better response. Supporting the oxidative stress theory, the results show promise for benzoate as a novel treatment for AD.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 76%

“… 45 In addition, the different findings between the primary and the secondary outcomes also support the notion that the ADAS‐cog is the gold standard for the AD clinical trials. 30 …”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

Lane

Wang

Lin

2022

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

Effects of Tai Chi on Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Lin

Cui

Yang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background and Purpose. Mild cognitive impairment (MCI) is a common condition, which threatens the quality of life of older adults. Tai Chi (TC) is growing in popularity among patients with MCI. This study is aimed at evaluating the effectiveness and safety of TC in older adults with MCI. Design. Randomized controlled trials (RCTs) from multiple databases from inception to December 2020 published in English were searched. Two researchers independently performed eligible study screening and data extraction. The methodological quality was assessed with the Jadad score. Meta-analysis of RCTs on TC in the treatment of MCI was performed with RevMan Version 5.4.1. Results. Seven RCTs with 1265 participants were included. For most RCTs, the overall reporting of methodological quality was high. Results of the meta-analysis indicate that TC improved MCI patients’ cognitive function significantly, including overall cognitive function ( MD = − 2.24 , 95% CI -3.51 to -0.97, P = 0.0005 ), memory and learning ( SMD = 0.83 , 95% CI 0.22 to 1.45, P = 0.008 ), visuospatial ability ( MD = 3.15 , 95% CI 0.74 to 5.56, P = 0.01 ), executive functions ( MD = 0.32 , 95% CI 0.03 to 0.61, P = 0.03 ), and physical activity ( MD = 18.78 , 95% CI 10.80 to 26.76, P < 0.00001 ). However, no significant benefit was found for TC on psychological activity ( MD = 0.17 , 95% CI -0.62 to 0.96, P = 0.36 ) and biomarker improvement. Conclusion. The meta-analysis confirmed the clinical therapeutic effect of TC for MCI. More rigorous and long-term follow-up RCTs should be conducted in the future.

show abstract

Hearing intervention for decreasing risk of developing dementia in elders with mild cognitive impairment: study protocol of a multicenter randomized controlled trial for Chinese Hearing Solution for Improvement of Cognition in Elders (CHOICE)

Chen,

Guan,

Chen

et al. 2023

Trials

View full text Add to dashboard Cite

Background Age-related hearing loss (ARHL) signifies the bilateral, symmetrical, sensorineural hearing loss that commonly occurs in elderly individuals. Several studies have suggested a higher risk of dementia among patients diagnosed with ARHL. Although the precise causal association between ARHL and cognitive decline remains unclear, ARHL has been recognized as one of the most significant factors that can be modified to reduce the risk of developing dementia potentially. Mild cognitive impairment (MCI) typically serves as the initial stage in the transition from normal cognitive function to dementia. Consequently, the objective of our randomized controlled trial (RCT) is to further investigate whether the use of hearing aids can enhance cognitive function in older adults diagnosed with ARHL and MCI. Methods and design This study is a parallel-arm, randomized controlled trial conducted at multiple centers in Shanghai, China. We aim to enlist a total of 688 older adults (age ≥ 60) diagnosed with moderate-to-severe ARHL and MCI from our four research centers. Participants will be assigned randomly to either the hearing aid fitting group or the health education group using block randomization with varying block sizes. Audiometry, cognitive function assessments, and other relevant data will be collected at baseline, as well as at 6, 12, and 24 months post-intervention by audiologists and trained researchers. The primary outcome of our study is the rate of progression to dementia among the two groups of participants. Additionally, various evaluations will be conducted to measure hearing improvement and changes in cognitive function. Apart from the final study results, we also plan to conduct an interim analysis using data from 12-month follow-up. Discussion In recent years, there has been a notable lack of randomized controlled trials (RCTs) investigating the possible causal relationship between hearing fitting and the improvement of cognitive function. Our findings may demonstrate that hearing rehabilitation can be a valuable tool in managing ARHL and preventing cognitive decline, which will contribute to the development of a comprehensive framework for the prevention and control of cognitive decline. Trial registration Chinese Clinical Trial Registry chictr.org.cn ChiCTR2000036139. Registered on 21 August 2020.

show abstract

Comparing the Standard and Electronic Versions of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale: A Validation Study

Cited by 3 publications

References 15 publications

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease

Effects of Tai Chi on Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Hearing intervention for decreasing risk of developing dementia in elders with mild cognitive impairment: study protocol of a multicenter randomized controlled trial for Chinese Hearing Solution for Improvement of Cognition in Elders (CHOICE)

Contact Info

Product

Resources

About